Commentary|Videos|February 18, 2025
SCOPE Summit 2025: Samuel Salvaggio Discusses Crucial Partnerships for Trial Efficiency
Author(s)Don Tracy, Associate Editor
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Samuel Salvaggio Senior Trial Design Lead, One2Treat, discusses partnerships that remain vital for guaranteeing success in clinical trial efficiency.
Advertisement
ACT: What types of partnerships—whether with CROs, technology vendors, or patient advocacy groups—do you see as crucial for improving trial efficiency and success?
Salvaggio: From my point of view, we principally work with site investigators and patient representatives. At One2Treat, we give tools for sponsors to interact with patient representative groups and site investigators, so they can get feedback on the best way to assess their treatment efficacy. By doing that, we think that it gives more value to the treatment that is being assessed, because now you can really measure what truly matters to these stakeholders.
Full Interview Summary: One2Treat s attending SCOPE to explore innovations in clinical trial operations, with a strong focus on patient-centric trial design. They highlight the event’s diverse range of participants, including companies, vendors, startups, and sponsors, all contributing to discussions on trial advancements.
While decentralized trials, real-world data integration, and AI-driven protocols are major industry trends, the speaker is primarily interested in how patient voices can be effectively integrated into trial design. They note that while the FDA has recently issued guidance on patient inclusion, it lacks detailed implementation strategies. Conferences like SCOPE provide a platform to discuss concrete methods for incorporating patient perspectives into trial strategies.
Regarding partnerships, Salvaggio emphasizes the importance of collaboration with site investigators and patient representatives. These stakeholders play a crucial role in ensuring that trials are designed with patient needs and experiences in mind, ultimately improving trial success and patient engagement.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
eClinical Technology: Misconceptions, Challenges, and Opportunities
3
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
4
How Recent Policy Changes Could Impact Clinical Research
5